Famitinib Combined With SHR-A1811, Versus SHR-A1811 for CDK4/6 Inhibitors-resistent Advanced HR+/HER2- Breast Cancer With SNF4 Subtype
NCT07382687
·
clinicaltrials.gov ↗
PHASE3
Phase
NOT_YET_RECRUITING
Status
248
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
Interventions
DRUG:
SHR-A1811
DRUG:
Famitinib+SHR-A1811
Sponsor
Fudan University